Skip to main content

Table 4 Discontinuations owing to adverse events by age, treatment group, and neuropathic pain condition

From: Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies

 

Placebo,

n (%)a

Pregabalin 150

mg/day, n (%)a

Pregabalin 300

mg/day, n (%)a

Pregabalin 600

mg/day, n (%)a

DPN

    

   Age 18-64 y

14 (3.8)

3 (2.4)

14 (7.7)

42 (12.2)

   Age 65-74 y

12 (7.6)

3 (7.7)

9 (14.5)

26 (18.7)

   Age ≥75 y

3 (8.8)

1 (10.0)

3 (13.6)

7 (23.3)

PHN

    

   Age 18-64 y

4 (5.9)

5 (8.8)

3 (6.7)

12 (25.5)

   Age 65-74 y

11 (7.7)

5 (5.4)

8 (12.5)

15 (21.7)

   Age ≥75 y

9 (5.9)

11 (10.8)

32 (26.4)

13 (30.2)

  1. aSee Table 1 for total number of patients in each age group by treatment group and neuropathic pain condition
  2. DPN: diabetic peripheral neuropathy; PHN: postherpetic neuralgia